Q-omics provides the consensus-scored THRSP profile across patient tissues and cancer cell-line models. THRSP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THRSP is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, THRSP RNA expression shows 13,659 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where THRSP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THRSP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THRSP survival associations across molecular data types. THRSP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THRSP RNA expression–survival associations across cancer types. High THRSP expression shows unfavorable associations in KIRC and CHOL, but favorable associations in LIHC, ACC, THCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THRSP RNA expression.
This table summarizes THRSP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for THRSP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THRSP shows lower tumor expression in BRCA, KIRP, HNSC, LIHC and KIRC and higher tumor expression in THCA. The THCA box plot shows higher THRSP RNA expression in tumor versus normal tissue (log2 FC = +2.502, t-test p < 0.001).
This table shows molecular features associated with THRSP in patient tissues and cancer cell lines. In patient samples, THRSP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THRSP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
